BiotechTube

Bosutinib + Imatinib

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

Conditions

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

Trial Timeline

Jul 15, 2014 → Apr 17, 2020

NCT ID
NCT02130557

About Bosutinib + Imatinib

Bosutinib + Imatinib is a phase 3 stage product being developed by Pfizer for Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive. The current trial status is completed. This product is registered under clinical trial identifier NCT02130557. Target conditions include Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive.

What happened to similar drugs?

20 of 20 similar drugs in Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive were approved

Approved (20) Terminated (1) Active (0)
✅micafungin + posaconazoleAstellas PharmaApproved
✅PirtobrutinibEli LillyApproved
✅PirtobrutinibEli LillyApproved
✅Pirtobrutinib + IdelalisibEli LillyApproved
✅Ibrutinib 420 mg + Ibrutinib 560 mgJohnson & JohnsonApproved
✅Venetoclax + AzacitidineAbbVieApproved
✅Venetoclax + Azacitidine + AzacitidineAbbVieApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02130557Phase 3Completed
NCT00574873Phase 3Completed

Competing Products

20 competing products in Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
11
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
42
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
39
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
PRGN-3006 T CellsPrecigenPhase 1
27
BisantreneRace OncologyPhase 2
29
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
15
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
25
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
ZN-d5Zentalis PharmaceuticalsPhase 1
19
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
26
Pirtobrutinib + IbrutinibEli LillyPhase 3
47
LY2523355Eli LillyPhase 1
21
TomivosertibeFFECTOR TherapeuticsPhase 1
23
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
40